Clinical Trials in IBD
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
Evolving Treatment Landscape in IBD
Conventional Treatments for UC and CD
FDA-Approved Biologics for UC and CD
UC Treatment Pathway
Conventional and Evolving Treatment Strategies for CD
Limitations of Current Biologic Treatments for IBD
Unmet Therapy Needs in IBD
Importance of Randomized, Controlled Trials
Challenges in the Current IBD Clinical Trial Environment
Evolution of Outcomes Measures in IBD Trials
Select Investigational Therapies for UC and CD IL Inhibitors
Select Investigational Therapies for UC and CD Other Classes
Patient Barriers to Participating in IBD Trials
Patient Barriers to Participating in IBD Trials Patient Survey Results
Physician Barriers
Referring Patients to IBD Trials
Participating in an IBD Trial as an Investigator
Recruiting and Retaining Patients on Study
Novel Trial Designs in IBD
Summary and Concluding Remarks
Abbreviations